Abstract 4139: Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients
Authors: Kozma Chris M. , Slaton Terra , Ellis Lorie , McKenzie R S. 
Published: May 2015

Abstract
Background: MCL, a subtype of non-Hodgkin's lymphoma, has an aggressive clinical course & poor prognosis. Few studies have described treatment patterns & HRU in treated MCL patients (pts).
Methods: U.S. healthcare claims data (Truven Health) was used to identify adult pts with a new episode of MCL therapy (tx) (defined as no MCL tx claim in prior ≥ 12 months) occurring within 90 days of an MCL diagnosis, & ≥ 12 months enrollment before & after the first MCL tx claim (index date). Pts with claims for pregnancy or non-MCL txs were excluded. The identification period was from 2007 - 2011. MCL txs included bendamustine, bortezomib, busulfan, carboplatin, carmustine, cisplatin, cladribine, cyclophosphamide, cytarabine, doxorubicin, etoposide, fludarabine, ifosfamide, melphalan, MESNA, methotrexate, mitoxantrone, lenalidomide, pentostatin, procarbazine, rituximab, temsirolimus, vincristine, or combinations. Demographics, MCL treatment patterns & HRU were summarized using descriptive statistics. HRU patterns during the 12 months before & after initiating MCL tx were analyzed.
Results: This analysis identified 381 pts. Mean age was 65 (SD 12) years; 73% were male. Prior to 2010, more than 70% of initial txs consisted of one of the following regimens: 1) cyclophosphamide-doxorubicin-rituximab-vincristine, 2) rituximab monotherapy, 3) vincristine monotherapy or 4) cyclophosphamide-rituximab-vincristine. After 2010, more than 70% of initial txs consisted of 1) cyclophosphamide-doxorubicin-rituximab-vincristine, 2) bendamustine-rituximab, & 3) rituximab monotherapy. MCL tx claims were reported for a mean of 4.0 (SD 2.0) months per pt in the 12 months following the index date. The table reports HRU in the 12 months before & after initial MCL tx.
Conclusions: This observational study of 381 treated MCL pts reported significant HRU in the 12 months following initiation of MCL tx. These results provide an indicator of MCL disease burden & provide stakeholders an estimate of HRU upon which standardized costs may be imputed.
TableHRU Category12 monthspre-index12 months post-index% with ≥1 hospitalization45% (171/381)57% (219/381)Hospital days per patient* Mean (SD)5.2 (10.3)13.5 (20.4)% with ≥ 1 Emergency room (ER) visit32% (123/381)43% (163/381)ER visits per patient*Mean (SD)0.5 (1.3)0.8 (1.4)Number of outpatient encounters per patient, mean (SD)31 (20)63 (35)% with ≥ 1 claim for colony stimulating factor use21% (80/381)69% (261/381)% with ≥1 claim for red blood cell growth factor use2% (9/381)17% (65/381)% with ≥1 red blood cell transfusion3% (11/381)15% (59/381)*Includes patients with zero resource use in the category
Citation Format: Chris M. Kozma, Terra Slaton, Lorie Ellis, R S. McKenzie. Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4139. doi:10.1158/1538-7445.AM2014-4139